z-logo
open-access-imgOpen Access
Impact of the AurkA Phe31-Ile polymorphism as a predictive marker on the succeptibility of HNSCC patients to Cetuximab therapy
Author(s) -
Annekathrin Roth,
John Muth,
Guido Piontek,
Maria Buchberger,
Matthias Wirth,
Anja Pickhard
Publication year - 2019
Publication title -
laryngo-rhino-otologie
Language(s) - English
Resource type - Conference proceedings
eISSN - 1438-8685
pISSN - 0935-8943
DOI - 10.1055/s-0039-1686058
Subject(s) - cetuximab , kinase , cancer research , oncology , predictive marker , medicine , antibody , biology , monoclonal antibody , immunology , cancer , genetics

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom